In short
Clinical trials are studying Atuliflapon in adults with moderate to severe uncontrolled asthma. These studies look at whether it is effective and safe compared with placebo, and they measure outcomes such as time to the first asthma worsening event.
Key points
- Atuliflapon is being studied in clinical trials for adults with moderate to severe uncontrolled asthma. The main listed trial was a Phase 2 study and used a randomised, double-blind, placebo-controlled design. Researchers looked at whether Atuliflapon could improve clinical outcomes compared with placebo. The main endpoint was time to first CompEx Asthma event, which measures the first asthma worsening event. The trial was completed and enrolled 879 participants.
Trial overview
The listed study of Atuliflapon was a Phase 2 trial in adults with moderate to severe uncontrolled asthma. The study was designed to assess both efficacy and safety compared with placebo, which is an inactive treatment.
Study design and treatment groups
This was a randomised, double-blind, placebo-controlled study. Randomised means participants were assigned by chance to study groups, double-blind means neither the participants nor the study team knew who received which treatment, and placebo-controlled means results were compared with an inactive treatment group.
The interventions listed were Atuliflapon given by mouth once daily for twelve weeks, salbutamol by inhalation, and placebo to Atuliflapon. Salbutamol was listed as an intervention in the trial record, but the brief summary focused on Atuliflapon versus placebo for the main comparison.
Who could join the study
The target population was adult participants with moderate to severe uncontrolled asthma. The trial record does not give more detailed entry rules in the source provided, so the exact participation criteria are not available here.
What was measured
The main outcome was time to first CompEx Asthma event. This means the study measured how long it took before the first asthma worsening event happened during the trial. The brief summary says the study aimed to evaluate the clinical efficacy of Atuliflapon compared with placebo in adults with moderate to severe uncontrolled asthma.
Trial status and size
The study status was Completed. The enrollment number was 879, which means 879 people were planned or included in the trial record as the study size.
What this means for patients
Based on the available trial record, Atuliflapon has been tested in a controlled research setting for adults whose asthma was not well controlled. The study design was built to compare outcomes fairly against placebo, which helps researchers judge whether the treatment may make a difference. Because only one trial record is provided here, this article reflects that single study and does not include results beyond the trial status and design details.